Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 4, 2013, Pages

  Jakobsson, Joel ^a   Stridsberg, Mats ^b   Zetterberg, Henrik ^a,c   Blennow, Kaj ^a   Ekman, Carl Johan ^d   Johansson, Anette G M ^d   Sellgren, Carl ^d   Landén, Mikael ^a,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN B; LAMOTRIGINE; SECRETOGRANIN II;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CEREBROSPINAL FLUID; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; PSYCHOSIS;

EID: 84879627832     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.120170     Document Type: Article

References (54)

1. Belmaker RH. Bipolar disorder. N Engl J Med 2004;351:476-86.
2. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68:241-51.
3. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35:804-17.
4. Ekman CJ, Lind J, Ryden E, et al. Manic episodes are associated with grey matter volume reduction - a voxel-based morphometry brain analysis. Acta Psychiatr Scand 2010;122:507-15.
5. Fernandes BS, Gama CS, Cereser KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011;45:995-1004.
6. Fernandes BS, Gama CS, Walz JC, et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. J Psychiatr Res 2010;44:561-5.
7. Walz JC, Magalhaes PV, Giglio LM, et al. Increased serum neurotrophin-4/5 levels in bipolar disorder. J Psychiatr Res 2009;43:721-3.
8. Burgess TL, Kelly RB. Constitutive and regulated secretion of proteins. Annu Rev Cell Biol 1987;3:243-93.
9. Kim T, Tao-Cheng JH, Eiden LE, et al. Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell 2001;106:499-509.
10. Huh YH, Jeon SH, Yoo SH. Chromogranin B-induced secretory granule biogenesis: comparison with the similar role of chromogranin A. J Biol Chem 2003;278:40581-9.
11. Courel M, Soler-Jover A, Rodriguez-Flores JL, et al. Pro-hormone secretogranin II regulates dense core secretory granule biogenesis in catecholaminergic cells. J Biol Chem 2010;285:10030-43.
12. Bartolomucci A, Possenti R, Mahata SK, et al. The extended granin family: structure, function, and biomedical implications. Endocr Rev 2011;32:755-97.
13. Bartolomucci A, Pasinetti GM, Salton SR. Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders. Neuroscience 2010;170:289-97.
14. Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003;3:1486-94.
15. Mattsson N, Ruetschi U, Podust VN, et al. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem 2007; 103:1932-9.
16. Pasinetti GM, Ungar LH, Lange DJ, et al. Identification of potential CSF biomarkers in ALS. Neurology 2006;66:1218-22.
17. Rüetschi U, Zetterberg H, Podust VN, et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 2005;196:273-81.
18. Landén M, Grenfeldt B, Davidsson P, et al. Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia. Eur Neuropsychopharmacol 1999;9:311-315.
19. Iijima Y, Inada T, Ohtsuki T, et al. Association between chromogranin b gene polymorphisms and schizophrenia in the Japanese population. Biol Psychiatry 2004;56:10-7.
20. Takahashi N, Ishihara R, Saito S, et al. Association between chromogranin A gene polymorphism and schizophrenia in the Japanese population. Schizophr Res 2006;83:179-83.
21. Wu S, Ma J, Xing Q, et al. Further evidence that the chromogranin B gene confers predisposition to schizophrenia: a family-based association study in Chinese. J Neural Transm 2007;114:641-4.
22. Zhang B, Tan Z, Zhang C, et al. Polymorphisms of chromogranin B gene associated with schizophrenia in Chinese Han population. Neurosci Lett 2002;323:229-33.
23. Iwazaki T, Shibata I, Niwa S, et al. Selective reduction of chromogranin A-like immunoreactivities in the prefrontal cortex of schizophrenic subjects: a postmortem study. Neurosci Lett 2004;367:293-7.
24. Nowakowski C, Kaufmann WA, Adlassnig C, et al. Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia. Schizophr Res 2002;58:43-53.
25. Cordeiro ML, Umbach JA, Gundersen CB. Lithium ions up-regulate mRNAs encoding dense-core vesicle proteins in nerve growth factor-differentiated PC12 cells. J Neurochem 2000;75:2622-5.
26. McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics 2007;17:605-17.
27. Umbach JA, Zhao Y, Gundersen CB. Lithium enhances secretion from large dense-core vesicles in nerve growth factor-differentiated PC12 cells. J Neurochem 2005;94:1306-14.
28. Rydén E, Thase ME, Straht D, et al. A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr Scand 2009;120:239-46.
29. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003;53:1028-42.
30. Kadouri A, Corruble E, Falissard B. The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry 2007;7:7.
31. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
32. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35.
33. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844-50.
34. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33. quiz 34-57.
35. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993;88:791-804.
36. Stridsberg M, Eriksson B, Oberg K, et al. A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B. Regul Pept 2005;125:193-9.
37. Stridsberg M, Eriksson B, Janson ET. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regul Pept 2008;148:95-8.
38. Miyazaki T, Yamasaki M, Uchigashima M, et al. Cellular expression and subcellular localization of secretogranin II in the mouse hippocampus and cerebellum. Eur J Neurosci 2011;33:82-94.
39. Saria A, Troger J, Kirchmair R, et al. Secretoneurin releases dopamine from rat striatal slices: a biological effect of a peptide derived from secretogranin II (chromogranin C). Neuroscience 1993;54:1-4.
40. Agneter E, Sitte HH, Stockl-Hiesleitner S, et al. Sustained dopamine release induced by secretoneurin in the striatum of the rat: a microdialysis study. J Neurochem 1995;65:622-5.
41. Kirchmair R, Gander R, Egger M, et al. The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo. Circulation 2004;109:777-83.
42. Shyu WC, Lin SZ, Chiang MF, et al. Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke. J Clin Invest 2008;118:133-48.
43. Lichtenstein P, Yip BH, Bjork C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009;373:234-9.
44. O'Dushlaine C, Kenny E, Heron E, et al. Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol Psychiatry 2011;16:286-92.
45. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460:748-52.
46. Barch DM. Neuropsychological abnormalities in schizophrenia and major mood disorders: similarities and differences. Curr Psychiatry Rep 2009;11:313-9.
47. McIntosh AM, Harrison LK, Forrester K, et al. Neuropsychological impairments in people with schizophrenia or bipolar disorder and their unaffected relatives. Br J Psychiatry 2005;186:378-385.
48. Strasser HC, Lilyestrom J, Ashby ER, et al. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: a pilot study. Biol Psychiatry 2005;57:633-9.
49. Bora E, Fornito A, Yucel M, et al. The effects of gender on grey matter abnormalities in major psychoses: a comparative voxelwise meta-analysis of schizophrenia and bipolar disorder. Psychol Med 2011 Aug. 11:1-13.
50. Post RM, Leverich GS. Treatment of bipolar illness: a casebook of clinicians and patients. New York: W.W. Norton Press; 2008.
51. Perlis RH. Translating biomarkers to clinical practice. Mol Psychiatry 2011;16:1076-87.
52. Chang YC, Rapoport SI, Rao JS. Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem Res 2009;34:536-41.
53. Li N, He X, Zhang Y, et al. Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine. Int J Neuropsychopharmacol 2011;14:1091-8.
54. Grande I, Balanza-Martinez V, Jimenez-Arriero M, et al. Clinical factors leading to lamotrigine prescription in bipolar outpatients: subanalysis of the SIN-DEPRES study. J Affect Disord 2012;143:102-8.